Olezarsen: FDA approval and clinical impact in familial chylomicronemia syndrome (FCS).

Familial chylomicronemia syndrome (FCS) is a rare autosomal recessive disorder characterized by severe hypertriglyceridemia due to impaired lipoprotein lipase (LPL) function. Traditional treatments like dietary fat restriction and conventional lipid-lowering drugs offer limited benefit due to the underlying genetic deficiency. On December 19, 2024, the Food and Drug Administration approved olezarsen (Tryngolza), an antisense oligonucleotide targeting apolipoprotein C-III (apoC-III), for adults with FCS. By inhibiting apoC-III synthesis, olezarsen enhances LPL activity and facilitates triglyceride clearance. Phase 3 trials demonstrated a significant reduction in triglyceride levels and a marked decrease in pancreatitis episodes, establishing its therapeutic efficacy. Olezarsen is administered monthly via subcutaneous injection, with most adverse events being mild and transient, such as injection site reactions and occasional thrombocytopenia. While short-term outcomes are promising, long-term safety, cost-effectiveness, and broader accessibility remain key concerns. Furthermore, the drug exemplifies the integration of computational biology and precision medicine, laying the foundation for AI-driven innovations in managing rare lipid disorders. Overall, olezarsen represents a major advancement in FCS treatment, addressing an urgent unmet clinical need and reshaping the therapeutic landscape of ultra-rare metabolic diseases.